Drugs / Tifacogin
Tifacogin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00084071 | May 2004 → Jul 2008 | pneumonia | Novartis Pharmaceuticals | Completed | Missed primary |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tifacogin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00084071 ↗ |
| Known as | Extrinsic pathway inhibitor | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108792 ↗ |
| Known as | LAC-I | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108792 ↗ |
| Known as | SC-59735 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108792 ↗ |
| Known as | Tifacogina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108792 ↗ |
| Known as | Tifacogine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108792 ↗ |
| Action | Inhibit | “tissue factor pathway inhibitor” NCT00084071 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human tissue factor pathway inhibitor (tifacogin)” PMID 19284881 ↗ Mar 2009 |